Side-by-side · Research reference

OvagenvsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

ATheoreticalHUMAN-REVIEWED2/42 cited

BPhase 3AUTO-DRAFTED10/40 cited

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

Ovagen

Tesofensine

Primary target

Ovarian tissue chromatin complexes

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

Presumed physiological — Khavinson peptides described as regulatory, not replacement

—

Origin

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

Ovagen

Tesofensine

Standard dose

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

0.25–0.5 mg / dayAstrup 2008

Frequency

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Once daily, morning

Evidence basis

Theoretical / Russian-tradition

Phase 2b + ongoing Phase 3Astrup 2008

Duration

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

24 weeks per studied cycle

Route

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

—

Lower / starter dose

—

0.125 mg / day

Form

—

Oral capsule

Timing

—

Morning to avoid sleep disruption

Half-life

—

~9 days (very long)

04Side Effects & Safety

Parameter

Ovagen

Tesofensine

Reported adverse events

None documented in indexed literature

—

Theoretical hormonal effects

Ovarian stimulation — monitor for estrogen-sensitive conditions

—

Injection site reaction

Possible mild erythema (SQ route)

—

Long-term safety

Unknown — no PubMed-indexed RCTs

—

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Nausea

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

Ovagen

Tesofensine

1. Oral route

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

Oral capsule (investigational; not commercial).

2. Subcutaneous route

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

Swallow whole with water, morning only.

3. Cyclical protocol

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

Morning to mitigate insomnia. Do not dose evening.

4. Storage

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

Room temp ≤25 °C, dry place.

5. Caveat

—

Monitor BP + HR + mood. Avoid stimulants + MAOIs.